Physician profile
Nishant Poddar
NPI 1124387675
$4,740.12
in general payments reported to CMS, 2019-2025
27 companies · $46.34 in 2025
The $46.34 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,394 · 2020: $489 · 2021: $218 · 2022: $22.53 · 2023: $502 · 2024: $68.67 · 2025: $46.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $3,193.64 | 2019 | |
| Myriad Genetic Laboratories, INC. | $288.43 | 2023 | Myrisk |
| Astellas Pharma US INC | $199.98 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $156.97 | 2020-2025 | Imfinzi, Enhertu |
| Incyte Corporation | $134.64 | 2020-2023 | Jakafi |
| Seagen INC. | $134.06 | 2020-2021 | |
| Amgen INC. | $79.58 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $62.74 | 2020-2021 | |
| Daiichi Sankyo INC. | $61.84 | 2020-2024 | Injectafer, Enhertu |
| Kite Pharma, INC. | $53.35 | 2021-2023 | Yescarta |
| E.R. Squibb & Sons, L.L.C. | $50.09 | 2020 | |
| Lilly USA, LLC | $47.06 | 2020-2023 | Jaypirca, Verzenio |
| Tersera Therapeutics LLC | $32.10 | 2023 | Zoladex |
| Merck Sharp & Dohme LLC | $28.29 | 2020 | |
| Abbvie INC. | $25.60 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $24.66 | 2023 | Gamunex-C |
| Pharmacyclics LLC, An Abbvie Company | $22.60 | 2020 | |
| Morphosys, US INC. | $20.36 | 2023 | Monjuvi |
| Genentech USA, INC. | $19.46 | 2023 | Tecentriq |
| Taiho Oncology, INC. | $19.34 | 2020 | |
| Eisai INC. | $16.22 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $15.97 | 2024 | Libtayo |
| Janssen Biotech, INC. | $15.04 | 2020 | |
| Allergan, INC. | $13.54 | 2020 | |
| Advanced Accelerator Applications | $12.75 | 2020 | |
| Coherus Oncology, INC. | $11.81 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nishant Poddar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.